Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

An ethical framework for human embryology with embryo models

  • Rivron, Nicolas C.
  • Martinez Arias, Alfonso
  • Pera, Martin F.
  • Moris, Naomi
  • M'hamdi, Hafez Ismaili
A human embryo's legal definition and its entitlement to protection vary greatly worldwide. Recently, human pluripotent stem cells have been used to form in vitro models of early embryos that have challenged legal definitions and raised questions regarding their usage. In this light, we propose a refined legal definition of an embryo, suggest "tipping points" for when human embryo models could eventually be afforded similar protection to that of embryos, and then revisit basic ethical principles that might help to draft a roadmap for the gradual, justified usage of embryo models in a manner that aims to maximize benefits to society., We thank Laurent David, Sarah Franklin, Misao Fujita, Ohad Gafni, Jacob Hanna, Rudolf Jaenisch, Nick Hopwood, Kathy Niakan, Vincent Pasque, Peter Rugg-Gunn, the members of the life sciences committee of the German National Academy of Sciences Leopoldina, the members of the ethics task force of the Agence française de biomédecine, and the Dutch Beleidsmedewerkers, ministerie van volksgezondheid, welzijn en sport for the valuable discussions. Because our opinions might be different from theirs, our acknowledgment should not be considered as their endorsement. N.C.R. thanks the OEAW Austrian Academy of Sciences for receiving IMBA core funding and the European Research Council (ERC) for receiving funding under the European Union’s Horizon 2020 research and innovation program ERC-Co grant agreement No. 101002317, “BLASTOID: a discovery platform for early human embryogenesis.” A.M.A. thanks the European Research Council (grant agreement 834580) and Ministerio de Educacion y Ciencia del Gobierno de España. N.M. thanks the Francis Crick Institute for receiving its core funding from Cancer Research UK (CC2186), the UK Medical Research Council (CC2186), and the Wellcome Trust (CC2186), as well as from an MRC-AMED grant (MR/V005367/2).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Human stem cell-based embryo models: innovation, ethics, and policy

  • Martinez Arias, Alfonso
  • Yu, Leqian
The aim of this White Paper is to establish a foundational framework for research, technological development, and regulation in the emerging field of stem cell-based embryo models (SCBEMs). These models, generated from Pluripotent Stem Cells, are designed to recapitulate essential events in early stages of human development. They have the potential to illuminate the early stages of embryo development and implantation and hold promise as an avenue to address global health challenges, including infertility and pregnancy loss, congenital, neonatal and adult conditions, and the need for organ transplants. While SCBEMs are not a substitute for human embryos, their tractability for large-scale analysis and their abilities to model the earliest stages of embryonic development suggest that they will have a significant impact on reproductive biology and regenerative medicine. But SCBEMs do not just raise novel scientific questions; they pose ethical and legal questions that need to be addressed. The paper stems from a meeting of a core group of researchers that met at the Institut Pasteur in Paris in November 2024 and represents the views of an extended group that has worked to elaborate the documents as a consensus for the field. Here, we provide a framework to guide research in this new field. We do this by summarizing the state of the science, assessing current SCBEM research in relation to its primary future applications and addressing the need for continued ethical and regulatory oversight associated with this new field., The meeting at the Institut Pasteur that led to this paper was funded by the Institut Pasteur and the Agence Nationale de la Recherche (Laboratoire d’Excellence Revive, Investissement d’Avenir; ANR-10-LABX-73). The following authors declare funding for this article. V.P. is supported by The Research Foundation–Flanders (FWO; Odysseus Return Grant G0F7716N to V.P.; FWO grants G0C9320N and G0B4420N), Pandarome project 40007487 (G0I7822N) (funded by the FWO and F.R.S.-FNRS) under the Excellence of Science (EOS) programme, the KU Leuven Research Fund (C1 grants C14/21/19 and C16/25/020, IDN/25/004 and GSF/26/062). N.R. is supported by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (ERC-Co grant agreement no. 101002317, ‘BLASTOID: a discovery platform for early human embryogenesis’ to N.R.). F.L. is supported by the Swedish Research Council (2023-02582), Wallenberg Academy Fellow (KAW 2021.0188). N.d.G. receives funding through ZonMW (project no. 10250022120002) and through reNEW, the Novo Nordisk Foundation Center for Stem Cell Medicine (NNF21CC0073729). G.M. is supported by Italian Ministry of University and Research (M.U.R) Project PRIN P20224ZY5P funded by Next Generation EU National Recovery and Resilience Plan (PNRR). M.A.E. is supported by the National Key R&D Program of China (2025YFC3408900). M.S.I.’s research is supported by Gates Foundation [INV-062190], JNCASR, and BRIC0InStem. The rest of the authors declare that their contribution to this article is not supported by any specific funding. B.L. and T.C. are supported by the University Research Priority Program ‘Human Reproduction Reloaded’, University of Zurich, Zurich, Switzerland.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Human stem cell-based embryo models: innovation, ethics, and policy

  • Martinez Arias, Alfonso
  • Yu, Leqian
The aim of this White Paper is to establish a foundational framework for research, technological development, and regulation in the emerging field of stem cell-based embryo models (SCBEMs). These models, generated from Pluripotent Stem Cells, are designed to recapitulate essential events in early stages of human development. They have the potential to illuminate the early stages of embryo development and implantation and hold promise as an avenue to address global health challenges, including infertility and pregnancy loss, congenital, neonatal and adult conditions, and the need for organ transplants. While SCBEMs are not a substitute for human embryos, their tractability for large-scale analysis and their abilities to model the earliest stages of embryonic development suggest that they will have a significant impact on reproductive biology and regenerative medicine. But SCBEMs do not just raise novel scientific questions; they pose ethical and legal questions that need to be addressed. The paper stems from a meeting of a core group of researchers that met at the Institut Pasteur in Paris in November 2024 and represents the views of an extended group that has worked to elaborate the documents as a consensus for the field. Here, we provide a framework to guide research in this new field. We do this by summarizing the state of the science, assessing current SCBEM research in relation to its primary future applications and addressing the need for continued ethical and regulatory oversight associated with this new field., The meeting at the Institut Pasteur that led to this paper was funded by the Institut Pasteur and the Agence Nationale de la Recherche (Laboratoire d’Excellence Revive, Investissement d’Avenir; ANR-10-LABX-73). The following authors declare funding for this article. V.P. is supported by The Research Foundation–Flanders (FWO; Odysseus Return Grant G0F7716N to V.P.; FWO grants G0C9320N and G0B4420N), Pandarome project 40007487 (G0I7822N) (funded by the FWO and F.R.S.-FNRS) under the Excellence of Science (EOS) programme, the KU Leuven Research Fund (C1 grants C14/21/19 and C16/25/020, IDN/25/004 and GSF/26/062). N.R. is supported by the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (ERC-Co grant agreement no. 101002317, ‘BLASTOID: a discovery platform for early human embryogenesis’ to N.R.). F.L. is supported by the Swedish Research Council (2023-02582), Wallenberg Academy Fellow (KAW 2021.0188). N.d.G. receives funding through ZonMW (project no. 10250022120002) and through reNEW, the Novo Nordisk Foundation Center for Stem Cell Medicine (NNF21CC0073729). G.M. is supported by Italian Ministry of University and Research (M.U.R) Project PRIN P20224ZY5P funded by Next Generation EU National Recovery and Resilience Plan (PNRR). M.A.E. is supported by the National Key R&D Program of China (2025YFC3408900). M.S.I.’s research is supported by Gates Foundation [INV-062190], JNCASR, and BRIC0InStem. The rest of the authors declare that their contribution to this article is not supported by any specific funding. B.L. and T.C. are supported by the University Research Priority Program ‘Human Reproduction Reloaded’, University of Zurich, Zurich, Switzerland.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

An ethical framework for human embryology with embryo models

  • Rivron, Nicolas C.
  • Martinez Arias, Alfonso
  • Pera, Martin F.
  • Moris, Naomi
  • M'hamdi, Hafez Ismaili
A human embryo's legal definition and its entitlement to protection vary greatly worldwide. Recently, human pluripotent stem cells have been used to form in vitro models of early embryos that have challenged legal definitions and raised questions regarding their usage. In this light, we propose a refined legal definition of an embryo, suggest "tipping points" for when human embryo models could eventually be afforded similar protection to that of embryos, and then revisit basic ethical principles that might help to draft a roadmap for the gradual, justified usage of embryo models in a manner that aims to maximize benefits to society., We thank Laurent David, Sarah Franklin, Misao Fujita, Ohad Gafni, Jacob Hanna, Rudolf Jaenisch, Nick Hopwood, Kathy Niakan, Vincent Pasque, Peter Rugg-Gunn, the members of the life sciences committee of the German National Academy of Sciences Leopoldina, the members of the ethics task force of the Agence française de biomédecine, and the Dutch Beleidsmedewerkers, ministerie van volksgezondheid, welzijn en sport for the valuable discussions. Because our opinions might be different from theirs, our acknowledgment should not be considered as their endorsement. N.C.R. thanks the OEAW Austrian Academy of Sciences for receiving IMBA core funding and the European Research Council (ERC) for receiving funding under the European Union’s Horizon 2020 research and innovation program ERC-Co grant agreement No. 101002317, “BLASTOID: a discovery platform for early human embryogenesis.” A.M.A. thanks the European Research Council (grant agreement 834580) and Ministerio de Educacion y Ciencia del Gobierno de España. N.M. thanks the Francis Crick Institute for receiving its core funding from Cancer Research UK (CC2186), the UK Medical Research Council (CC2186), and the Wellcome Trust (CC2186), as well as from an MRC-AMED grant (MR/V005367/2).